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Proprotein convertase subtilisin/kexin type 9 (PCSK9), a liver-secreted plasma enzyme, restricts
hepatic uptake of low-density lipoprotein (LDL) cholesterol by promoting the degradation of LDL
receptors (LDLR). PCSK9 and LDLR are also expressed in insulin-producing pancreatic islet b cells,
possibly affecting the function of these cells. Here we show that, compared to control mice,
PCSK9-null male mice over 4 months of age carried more LDLR and less insulin in their pancreas;
they were hypoinsulinemic, hyperglycemic and glucose-intolerant; their islets exhibited signs of
malformation, apoptosis and inﬂammation. Collectively, these observations suggest that PCSK9
may be necessary for the normal function of pancreatic islets.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction LDL-C, leading to hypocholesterolemia [3,7]. Its overexpression inProprotein convertase subtilisin/kexin type 9 (PCSK9) belongs
to a 9-member family of serine endoproteinases, structurally re-
lated to bacterial subtilisin and to yeast kexin. These enzymes
are found in the secretory pathway of all cells, in varying combina-
tions and levels. Collectively, they are responsible for the activation
of a wide variety of precursor proteins by endoproteolysis after se-
lected residues [1]. PCSK9 is predominantly produced and secreted
by the liver [2,3]. It has no known physiological substrate.
The most studied property of PCSK9 is its ability to down regu-
late hepatic uptake of low-density lipoprotein-cholesterol (LDL-C)
by promoting intracellular degradation of the LDL receptor (LDLR).
According to the current prevailing model, the convertase attaches
to the receptor and directs it to endosomes/lysosome-like com-
partments for degradation [4–6]. Inactivation of the Pcsk9 gene in
mouse increases hepatic LDLR content and the clearance of plasmachemical Societies. Published by E
ecipitation; LDL, low-density
ceptor; OGTT, oral glucose
scriptase-polymerase chain
in type 9; sqIB, semi-quanti-
in
spital Research Institute, 725
ax: +1 613 761 4355.the liver of transgenic mice has the opposite effect [3,8–12].
Pancreatic b cells express signiﬁcant amounts of LDLR [13,14].
These receptors can mediate the uptake of exogenous lipoproteins
by established b cell lines and isolated islets in culture. Chronic
exposure to high LDL or VLDL is lethal for these cells [14,15]. Death
occurs through endogenous heavy metal-catalyzed oxidative stress
since it can be abrogated by chelating agents and antioxidants [15].
A survey of established cell lines indicated that RIN-m5F and bTC-3
lines derived from insulin-producing pancreatic b cells contained
substantial amounts of PCSK9 mRNA [2,3]. We hypothesized that
PCSK9 protects these cells from the toxic effects of excessive cho-
lesterol accumulation. Comparing wild type and PCSK9-null mice,
we show in this report that male mutant mice exhibit impaired
glucose homeostasis.2. Materials and methods
2.1. Mice
129Sv;C57BL/6 (129;B6) Pcsk9+/ male mice were purchased
from the Jackson Laboratory (Bar Harbor, ME) and were
backcrossed with B6 Pcsk9+/+ females for eight generations. The
B6-N8 Pcsk9+/ incipient congenic mice were then intercrossed tolsevier B.V. All rights reserved.
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5 months of age. Mice were treated according to guidelines of the
Canadian Council on Animal Care under a protocol approved by
an institutional Animal Care Committee. They were housed in tem-
perature-controlled (25 C) rooms with a 12-h light/dark cycle and
given access to standard mouse chow and water ad libitum, except
when overnight fasting (12–16 h) was required.
2.2. Oral glucose tolerance test (OGTT)
Mice were fasted overnight, weighed and blood (0.05 ml) was
collected by submandibular puncture and supplemented with
EDTA to a ﬁnal concentration of 10 mM. They were then fed glu-
cose (1.5 mg/g body weight) by oral gavage and were bled as above
after 15, 30, 60 and 120 min. Blood samples were centrifuged for
10 min at 1100g to sediment cells; plasma was collected and
stored at 80 C until analysis.
2.3. Pancreatic islet isolation and culture
Mouse pancreatic islets were isolated following ductal injection
of collagenase buffer (1.5 mg/ml) [16,17]. Brieﬂy, mice were anes-
thetized and sacriﬁced by cervical dislocation; pancreata were in-Fig. 1. Mouse pancreatic b cells express PCSK9 and LDLR. Pcsk9+/+ or Pcsk9/ male mice
RNA for qRT-PCR for PCSK9 and LDLR and TBP mRNAs, the latter serving as normalizing in
sqIB for LDLR (120 kDa) and b actin (35 kDa), the latter serving as a normalizing inter
pancreas than the Pcsk9+/+ mice. (C) MIN6 cells were metabolically labeled with [35S]-Met
forms. (D) MIN6 cell lysates and liver extracts from Pcsk9+/+ or Pcsk9/ mice were ana
receptor level in hepatic extracts from null mice.jected with a collagenase solution; islets were handpicked under
a microscope.
2.4. Glucose and insulin and lipid assays
Glucose levels were determined using the Beckman Coulter glu-
cose analyzer and insulin levels were measured using the Ultra
Sensitive Mouse Insulin ELISA Kit from Crystal Inc. (Downers
Grove, IL).
2.5. Quantitative reverse transcriptase-polymerase chain reaction
(qRT-PCR)
The levels of speciﬁc mRNAs were quantiﬁed in a PCR-based
ﬂuorogenic assay using the Taqman technology [18]. Brieﬂy, total
RNA was extracted using the RNeasy extraction kit from Qiagen
(Mississauga, ON) and reverse-transcribed into cDNA using ran-
dom hexameric primers and the Superscript II RNase H Reverse
Transcriptase (Invitrogen). The cDNA was used as a template to
produce PCR amplicons using FastStart TaqMan ProbeMaster-Rox
master mix, primer pairs and the appropriate ﬂuorescent probe
from the Universal Probe Library (UPL) (Roche, Laval, QC) (Supple-
mentary Table 1S) in a Mx3005P thermocycler (Stratagene, LaJolla,were used (n = 4/genotype). (A) Isolated pancreatic islets were used as the source of
ternal control. (B) Whole pancreas extracts (n = 4 mice/genotype) were analyzed by
nal control. Pcsk9/ mice contained twofold (P < 0.05) more LRLR protein in their
/Cys for 6 h. The cell lysate and spent medium were analyzed by IP of PCSK9-related
lyzed by sqIB for LDLR (120 kDa) and a-tubulin (55 kDa). Note the increase in the
Fig. 3. OGTT. Pcsk9+/+ and Pcsk9/male mice (n = 9/genotype) were subjected to an
OGTT. (A) Plasma glucose was not different between the two genotypes at 15 min,
but was signiﬁcantly higher in mutant mice at later time points. (B) Plasma insulin
was signiﬁcantly lower in mutant mice at all time points, most noticeably at
15 min. *P < 0.05; ***P < 0.001.
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pre-quantiﬁed amplicons of each transcript. The level of mRNA
for the TATA-box binding protein (TBP) was used for
normalization.
2.6. Histology
Parafﬁn sections (5 lm thickness) were deparafﬁnized using
CitriSolv and rehydrated with graded ethanol (100%, 95%, and
75% ethanol) and H2O. Gill’s hematoxylin solution (No. 2) was used
for nuclear staining and 0.5% eosin solution for cytoplasm staining.
Apoptosis, tubular complexes and inﬂammation were evaluated
morphologically using previously deﬁned characteristics [19].
2.7. Metabolic labeling, immunoprecipitation (IP) and immunoblotting
(IB)
The details of these procedures are described in Supplementary
data.
2.8. Statistical analyses
Results are expressed as means ± standard errors of means
(SEM). Differences between experimental groups were analyzed
by unpaired Student t-test. Signiﬁcance of differences was set at
P < 0.05.
3. Results
3.1. PCSK9 and LDLR expression in pancreatic islets
PCSK9 mRNA was below detection by qRT-PCR in RNA extracted
from whole pancreas [3]. Because pancreatic islet cell lines have
been shown to contain this transcript [2], we isolated pancreatic is-
lets from Pcsk9+/+ and Pcsk9/ mice and analyzed their RNA by
qRT-PCR for both PCSK9 and LDLR mRNA levels using TBP mRNA
level for normalization. LDLR transcripts were present at similar
levels in islets from Pcsk9+/+ and Pcsk9/ mice; Pcsk9 transcripts
were present in islets from Pcsk9+/+ mice only (Fig. 1A).
Semi-quantitative immunoblotting (sqIB) analysis of proteins
extracted from whole pancreas showed that Pcsk9/ mice con-
tained twofold more LDLR in this organ than Pcsk9+/+ mice
(P < 0.05) (Fig. 1B). Since the anti-mouse PCSK9 antibody available
to us unambiguously recognized this protein in mouse plasma butFig. 2. Glucose homeostasis is altered in PCSK9-deﬁcient mice. Female (F) and male (M)
for glucose homeostasis parameters. (A) Fasting glycemia was similar in females; but was
male Pcsk9/ mice. (C) Pancreatic insulin content was reduced (P < 0.05) in Pcsk9/ mnot tissue extracts and only by IP [3], we examined for possible co-
expression of PCSK9 and LDLR in mouse insulinoma MIN6 cells.
These cells were grown in medium containing 35S-Met/Cys to met-, Pcsk9+/+ and Pcsk9/ 4-month-old mice (n = 8/gender/genotype) were phenotyped
increased (P < 0.05) in male Pcsk9/mice. (B) Insulinemia was reduced (P < 0.01) in
ice.
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cell lysates were subjected to IP using the anti-mouse PCSK9 anti-
body and the precipitates analyzed by SDS–PAGE followed by
phosphorimaging. Cell lysates contained immunoreactive proteins
of 72, 62, and 50 kDa corresponding to the mass expected for proP-
CSK9, PCSK9, and the furin-cleaved DNT218-PCSK9, respectively
(Fig. 1C, lane 1) (see also diagrams in Supplementary Fig. 1S). Spent
media contained predominantly the 62-kDa form (Fig. 1C, lane 2).
By IB, LDLR was detected in MIN6 cells at levels comparable to that
of normal liver (Fig. 1D, lane 1 vs 2).
3.2. Plasma glucose, plasma insulin and glucose tolerance
Before 4 months of age, there was no signiﬁcant difference in
fasting plasma glucose and insulin between Pcsk9/ and Pcsk9+/+
mice within gender. At 4 months, fasting plasma glucose was sig-Fig. 4. Pancreatic histology. Whereas pancreatic islets from Pcsk9+/+ mice appeared gen
(panel C), with most b-cells displaying eosinophilic cytoplasm and condensed nuclei (pan
were sites of inﬂammation (outlined in panel E) and occasional tubular complexes (outniﬁcantly higher in male Pcsk9/ mice relative to Pcsk9+/+ mice
(P < 0.05), but remained similar between genotypes in female mice
(Fig. 2A). Subsequent studies were conducted with male mice only.
Fasting plasma insulin in Pcsk9/ mice was about half that of
Pcsk9+/+ mice (P < 0.01) (Fig. 2B). The pancreas from Pcsk9/ mice
contained 30% less insulin than those from Pcsk9+/+ mice
(P < 0.05) (Fig. 2C), suggesting that the mutant may suffer from
insulin insufﬁciency.
In an OGTT, glycemia was elevated but similar between the two
genotypes at 15 min post-oral glucose administration; at subse-
quent time points up to 120 min, it declined in Pcsk9+/+ mice but
remained signiﬁcantly higher in Pcsk9/ mice (P < 0.05) (Fig. 3A).
At 15 min, insulinemia dramatically increased in Pcsk9+/+ mice,
but barely changed in Pcsk9/ mice (P < 0.001); it returned to
pre-gavage levels at subsequent time points (Fig. 3B).erally normal (panels A and B), those for Pcsk9/ often exhibited irregular shapes
el D), suggesting early apoptosis. Also observed in the pancreas of these mutant mice
lined in panel F). Bar = 250 lm in panels (A) and (C); 50 lm in panels (B), (D–F).
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Histological analysis of pancreas sections indicated that, com-
pared to Pcsk9+/+ mice (Fig. 4A and B), Pcsk9 / mice often exhib-
ited islets of irregular shapes (Fig. 4C), with most b-cells displaying
eosinophilic cytoplasm and condensed nuclei (Fig. 4D), suggestive
of early apoptosis. Also observed in the pancreas of these mutant
mice were sites of inﬂammation (Fig. 4E) and occasional tubular
complexes (Fig. 4F). These complexes represent transitional struc-
tures involved in islet neogenesis [19].
4. Discussion
Data presented in this report show that, as they age, PCSK9-
deﬁcient male mice exhibit mild chronic hyperglycemia and im-
paired glucose tolerance. Their pancreatic content and plasma lev-
els of insulin are reduced, suggesting insulin insufﬁciency. Their
pancreatic islets are morphologically abnormal, showing signs of
inﬂammation and early apoptosis. Cholesterol accumulation in
the islets of PCSK9-deﬁcient could be a cause of these abnormali-
ties, considering mounting experimental evidence of the toxic ef-
fect of accumulation of this sterol in b cells [20,21]. This
accumulation is an expected consequence of the lack of PCSK9-
mediated down regulation of pancreatic islet LDLR and of LDL-C
uptake via this receptor.
However, an LDLR-independent effect of PCSK9 deﬁciency re-
mains a possibility. Experimental evidence suggests that this pro-
tein may play a role in organ development and repair. Elevated
expression of its mRNA precedes liver regeneration following par-
tial hepatectomy [3]. Furthermore, liver from PCSK9-null mice can-
not regenerate following partial hepatectomy and undergoes
necrosis [3]. Pancreatic islets can be renewed and the pancreas
can regenerate following partial pancreatectomy [22]. It would
be interesting to determine whether PCSK9 plays any role in this
process.
Gender, age, modiﬁer genes, and diet are factors known to con-
tribute to deterioration of glucose homeostasis in susceptible sub-
jects. In PCSK9-null male mice, this deterioration becomes
observable at 4 months of age. The reduced susceptibility of female
mice to this process has been observed with other mouse models
[23,24]. This dichotomy is attributed to the beneﬁcial effects of fe-
male sex hormones on b cell functions [25].
The relevance of this mouse model of global PCSK9 deﬁciency
to the pathogenesis of diabetes in humans is unclear. Although
several PCSK9 single-nucleotide polymorphisms associated with
persistently low plasma cholesterol have been identiﬁed in the
human genome [26], no case of PCSK9 nullizygosity has ever
been reported. Interestingly, in a 1984 large California study
comparing individuals across deciles of plasma cholesterol levels
for sociologic, biologic, and medical characteristics, a greater
prevalence of diabetes was unexpectedly noted in individuals
in the lowest decile of cholesterolemia [27]. These diabetics also
exhibited a greater body mass index and higher plasma triglyc-
erides levels than non-diabetics in the same decile or diabetics
in higher deciles, suggesting that other metabolic dysfunctions
contributed to this association. Whether PCSK9 deﬁciency could
inﬂuence the onset of such a syndrome will require more
studies.
In conclusion, data presented in this report suggest total PCSK9
deﬁciency may deleteriously affect glucose homeostasis.
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